Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $6.6500 (-5%) ($6.4750 - $6.8572) on Tue. Nov. 24, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.22% (three month average) | RSI | 15 | Latest Price | $6.6500(-5%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -1.6% a day on average for past five trading days. | Weekly Trend | HTBX declines -5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(34%) XBI(34%) ARKK(33%) BLOK(32%) IBB(31%) | Factors Impacting HTBX price | HTBX will decline at least -2.61% in a week (0% probabilities). VXX(-21%) VIXM(-21%) UUP(-15%) XLU(-4%) XLP(-3%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.61% (StdDev 5.22%) | Hourly BBV | 0.2 () | Intraday Trend | -2.1% | | | |
|
1 - 5 Day Possible Target | $-6.69(-200.6%) | Resistance Level | $7.56 | 5 Day Moving Average | $7(-5%) | 10 Day Moving Average | $7.15(-6.99%) | 20 Day Moving Average | $7.56(-12.04%) | To recent high | -32.6% | To recent low | 0% | Market Cap | $732m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |